TITLE

Antiviral Briefs

PUB. DATE
November 2008
SOURCE
AIDS Patient Care & STDs;Nov2008, Vol. 22 Issue 11, p917
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to developments related to antiviral agents. Pfizer Inc. has released data from a study of HIV patients, in which findings point to the need for proper patient selection prior to treatment with CCR5 therapies. The U.S. Food and Drug Administration (FDA) granted tentative approval for a generic formulation of lamivudine manufactured by Macleods Pharmaceuticals Ltd. The FDA has approved a pediatric efficacy supplement for Retrovir syrup, capsules and tablets.
ACCESSION #
35407605

 

Related Articles

  • New class of anti-HIV drug approved.  // European Pharmaceutical Executive;Jun2007, p9 

    The article reports on the recommendation of the U.S. Food and Drug's (FDA) Antiviral Drugs Advisory Committee on the approval of Pfizer Inc.'s maraviroc, a chemokine receptor (CCR5) antagonist. It is designed to treat patients infected with CCR5-tropic human immunodeficiency virus-1 (HIV),...

  • FDA panel OKs new class of HIV drug. Roehr, Bob // Bay Area Reporter;4/26/2007, Vol. 37 Issue 17, p17 

    The article reports that a committee of the U.S. Food and Drug Administration has recommended approval of Pfizer Inc.'s CCR5 inhibitor maraviroc, trademarked Celsentri. Maraviroc belongs to a class of anti-HIV drugs developed for heavily treatment-experienced patients. It works against the R5...

  • FDA Actions.  // Critical Care Alert;Dec2009 Pharmacology Watch, p2 

    The article reports on the approval of the Food and Drug Administration (FDA) on the use of IV antiviral peramivir for treatment of inpatients with 2009 H1N1 influenza in the U.S.

  • New molecular entities/new biologics.  // Formulary;Apr2003, Vol. 38 Issue 4, p182 

    Reports on the U.S. Food and Drug Administration's approval of enfuvirtide, an anti-HIV drug. Efficacy; Safety; Dosing; Availability; Cost.

  • Remoxy: more work needed for FDA approval.  // Reactions Weekly;7/9/2011, Issue 1359, p3 

    The article reports on the rejection received by Pfizer from the U.S. Food and Drug Administration (FDA) for its extended-release formulation Remoxy.

  • Celebrex Loses FAP Indication.  // BioWorld Today;6/11/2012, Vol. 23 Issue 112, p6 

    The article reports on the decision of the U.S. Food and Drug Administration to pull out its 12-year-old accelerated approval for Celebrex, the drug for familial adenomatous polyposis (FAP) from Pfizer Inc. because the postmarketing study required to verify the clinical benefit was not completed.

  • Pharma: Other News To Note.  // BioWorld Today;11/6/2013, Vol. 24 Issue 214, p13 

    The article informs that Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) approved a prior approval supplement for Embeda extended-release capsule Schedule II Controlled Substance (CII).

  • FDA approves new treatment for menopause.  // Hill;10/7/2013, Vol. 20 Issue 113, p15 

    The article reports that U.S. Feederal Drug Administration (FDA) has approved the utilization of Duavee, a drug that prevents menopausal osteoporosis and other symptoms, developed by Pfizer Inc.

  • Pfizer, Inc.; Withdrawal of Approval of Familial Adenomatous Polyposis Indication for CELEBREX. Woodcock, Janet // Federal Register (National Archives & Records Service, Office of;6/8/2012, Vol. 77 Issue 111, p34052 

    The article presents information on a notice issued by the U.S. Food and Drug Administration regarding the withdrawal of approval for the familial adenomatous polyposis for celecoxib capsules which is offered by Pfizer Inc.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics